Core Insights - Allworth Financial LP significantly increased its position in Neurocrine Biosciences by 2,107.4% in Q2, owning 2,980 shares valued at $375,000 [2] - Other institutional investors also increased their stakes, with Dodge & Cox raising its position by 83.5% and Los Angeles Capital Management by 19,454.9% in Q2 [3] - Analysts have a positive outlook on Neurocrine Biosciences, with multiple firms raising their price targets and maintaining buy ratings [4] Institutional Investment - Allworth Financial LP acquired an additional 2,845 shares in Q2, bringing its total to 2,980 shares [2] - Dodge & Cox now owns 5,534,624 shares worth $612.13 million after acquiring 2,518,199 shares [3] - Los Angeles Capital Management LLC increased its holdings to 744,650 shares valued at $93.60 million after purchasing 740,842 shares [3] Analyst Ratings - Wedbush maintains an "outperform" rating for Neurocrine Biosciences [4] - Canaccord Genuity raised its target price from $160.00 to $164.00, while Citigroup increased its target from $175.00 to $203.00 [4] - The consensus rating for Neurocrine Biosciences is "Moderate Buy" with a target price of $170.53 [4] Financial Performance - Neurocrine Biosciences reported Q3 earnings of $2.17 per share, exceeding estimates by $0.59, with revenue of $794.90 million, up 27.8% year-over-year [6] - The company has a market capitalization of $14.44 billion and a P/E ratio of 34.66 [5] Insider Activity - CEO Kyle Gano sold 300 shares at an average price of $141.97, reducing his ownership by 0.21% [7] - Director William H. Rastetter sold 18,000 shares at an average price of $151.82, representing a 30.84% decrease in ownership [7] Company Overview - Neurocrine Biosciences focuses on pharmaceuticals for neurological and neuropsychiatric disorders, with products including INGREZZA and ALKINDI [8]